Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Journal of neural transmission. Supplementum

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-7091-3345-3_4PMID 2202785
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Arginine vasopressin, but not corticotropin releasing factor, is a potent stimulator of adrenocorticotropic hormone following electroconvulsive treatment

  2005cited by this paper
• Distribution of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in human brain in relation to age, drug influence, agonal status and circadian variation

  2005cited by this paper
• The Clinical Efficacy of Citalopram in Treatment of Emotional Disturbances in Dementia Disorders a Nordic Multicentre Study

  1990cited by this paper
• Early Stages of Late Onset Alzheimer's Disease

  1989cited by this paper
• Neurotransmitter deficits in a non‐multi‐infarct category of vascular dementia

  1989cited by this paper
• Tyrosine hydroxylase, tryptophan hydroxylase, and the biopterin cofactor in the brains from patients with Alzheimer's disease

  1989cited by this paper
• Relationship between DST and the serotonergic system. Results from treatments with two 5‐HT reuptake blockers in dementia disorders

  1988cited by this paper
• Peripheral serotoninergic receptor sensitivity in senile dementia of the Alzheimer type.

  1988cited by this paper
• The clonidine test in patients with dementia disorders: Relation to clinical status and cerebrospinal fluid metabolite levels

  1988cited by this paper
• Low B12 levels related to high activity of platelet MAO in patients with dementia disorders

  1988cited by this paper
• Alzheimer's disease. A critical review.

  1988cited by this paper
• 5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders.

  1987cited by this paper
• Neurotransmitters in Old Age and Dementia

  1986cited by this paper
• Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type.

  1986cited by this paper
• Multiple biochemical deficits in both gray and white matter of Alzheimer brains.

  1986cited by this paper
• Transmitter deficits in Alzheimer's disease.

  1985cited by this paper
• Changes of Biogenic Amines and Their Metabolites in Postmortem Brains from Patients with Alzheimer‐Type Dementia

  1984cited by this paper
• Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).

  1983cited by this paper
• Serotonin nerve cells in Alzheimer's disease.

  1983cited by this paper
• Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism.

  1980cited by this paper
• Acid monoamine metabolites in cerebrospinal fluid from patients with presenile dementia (Alzheimer's disease).

  1973cited by this paper
• ACID MONOAMINE METABOLITES IN CEREBROSPINAL FLUID FROM PATIENTS WITH PRESENILE DEMENTIA (ALZHEIMER'S DISEASE)

  1973cited by this paper
• Acid monoamine metabolites in human cerebrospinal fluid and their relations to age and sex.

  1971cited by this paper
• HOMOVANILLIC ACID AND 5‐HYDROXYINDOLEACETIC ACID IN THE CEREBROSPINAL FLUID OF PATIENTS WITH SENILE DEMENTIA, PRESENILE DEMENTIA AND PARKINSONISM

  1969cited by this paper

• Neurotransmitters and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets

  2025cites this paper
• Deciphering the Functions of Raphe–Hippocampal Serotonergic and Glutamatergic Circuits and Their Deficits in Alzheimer’s Disease

  2025cites this paper
• Neural circuits expressing the serotonin 2C receptor regulate memory in mice and humans

  2024cites this paper
• Putative pathological mechanisms of late-life depression and Alzheimer's Disease.

  2023cites this paper
• Monoamines and their derivatives on GPCRs: potential therapy for Alzheimer's Disease.

  2019cites this paper
• Pharmacological Treatment of Depression in Alzheimer’s Disease: A Challenging Task

  2019cites this paper
• Serotonergic system, cognition, and BPSD in Alzheimer's disease.

  2019cites this paper
• Neural activity, memory, and dementias: serotonergic markers

  2017cites this paper
• The role of serotonin receptors in Alzheimer’s disease

  2016cites this paper
• Vagus nerve stimulation in patients with Alzheimer ’s disease

  2015cites this paper
• Limited Effects of an eIF2α S51A Allele on Neurological Impairments in the 5xFAD Mouse Model of Alzheimer's Disease

  2015cites this paper
• Pattern of tau hyperphosphorylation and neurotransmitter markers in the brainstem of senescent tau filament forming transgenic mice.

  2013cites this paper
• The serotonergic system in ageing and Alzheimer's disease.

  2012cites this paper
• Altered serotonergic neurotransmission as a main player in the pathophysiology of Alzheimer's disease : structural and ultrastructural studies in a triple transgenic mouse model of the disease

  2012cites this paper
• tauopathy alters serotonin metabolism and breathing activity in terminal au . P 301 L mice : Possible implications for tauopathies and Alzheimer ’ s disease

  2011cites this paper
• Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.

  2011cites this paper
• Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease

  2010cites this paper
• Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease.

  2009cites this paper
• Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice.

  2007cites this paper
• The neurotoxin 2'-NH2-MPTP degenerates serotonin axons and evokes increases in hippocampal BDNF.

  2006cites this paper
• CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor.

  2006cites this paper
• Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice.

  2005cites this paper
• Serotonin, Kognition, Demenz

  2005cites this paper
• Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease

  2004influential citation
• 2′-NH2-MPTP [1-Methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2′-CH3-MPTP [1-Methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine]

  2002cites this paper
• 2 (cid:1) -NH 2 -MPTP [1-Methyl-4-(2 (cid:1) -aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2 (cid:1) -CH 3 -MPTP [1-Methyl-4-(2 (cid:1) -methylphenyl)-1,2,3,6-tetrahydropyridine]

  2002cites this paper
• 2 (cid:1) -NH 2 -MPTP [1-Methyl-4-(2 (cid:1) -aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2 (cid:1) -CH 3 -MPTP [1-Methyl-4-(2 (cid:1) -methylphenyl)-1,2,3,6-tetrahydropyridine]

  2002cites this paper
• Preclinical progress with CHF2819, a novel orally active acetylcholinesterase inhibitor

  2002cites this paper
• Tryptophan degradation and immune activation in Alzheimer's disease

  2000cites this paper
• The evolution of Alzheimer's disease‐related cytoskeletal pathology in the human raphe nuclei

  2000cites this paper
• Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.

  2000cites this paper
• Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer’s disease (DAT): Lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT

  1998cites this paper
• Depression and Alzheimer’s Disease

  1997cites this paper
• Selective decline of 5-HT1A receptor binding sites in rat cortex, hippocampus and cholinergic basal forebrain nuclei during aging.

  1997cites this paper
• Long-Term Treatment of Elderly Individuals With Emotional Disturbances: An Open Study With Citalopram

  1996cites this paper
• Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor

  1995cites this paper
• Abnormalities in Non-Cholinergic Neurotransmitter Systems in Alzheimer’s Disease

  1994cites this paper
• Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism.

  1994cites this paper
• Alzheimer's disease: improvement of visual memory and visuoconstructive performance by treatment with picotesla range magnetic fields.

  1994cites this paper
• Fluvoxamine treatment of dementia: tryptophan levels.

  1993cites this paper
• Neurotransmitter Interactions and Responsivity to Cholinomimetic Agents

  1992cites this paper
• Review of treatment strategies

  1992cites this paper
• Störungen der monoaminergen Neurotransmittersysteme bei Demenz vom Alzheimer-Typ

  1992cites this paper
• Neurotransmitter Interactions and Cognitive Function

  1992cites this paper
• Fluvoxamine in the treatment of demented elderly patients: a double‐blind, placebo‐controlled study

  1992cites this paper
• Neurotransmitter, receptor and signal transduction disturbances in Alzheimer's disease

  1992cites this paper
• L-tryptophan in neuropsychiatric disorders: a review.

  1992cites this paper
• The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach.

  1991cites this paper
• A concise synthesis of [carbonyl‐11C]melatonin and N‐[carbonyl‐ 11C]acetylserotonin

  1991cites this paper
• Neurochemical aspects on aging and diseases with cognitive impairment

  1990cites this paper